Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
99.00    0.00 (0.00%)
Bid:
98.90
Ask:
99.90
Spread: 1.00 (1.011%)
Market Cap: £602.11m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Proposed changes to expense arrangements

24 Nov 2015 10:40

BACIT LIMITED - Proposed changes to expense arrangements

BACIT LIMITED - Proposed changes to expense arrangements

PR Newswire

London, November 24

BACIT LIMITED(a closed-ended investment company incorporated in Guernseywith registration number 55514)

(the "Company")

24 November 2015

Proposed changes to expense arrangements

The Company announces a proposed change to the basis on which the operating expenses of BACIT (UK) Limited, the Company’s investment manager (the “Investment Manager”), are paid with effect from 1 January 2016. The proposed change is subject to shareholder approval. 

The key features of the Company’s investment policy — that it will invest in underlying funds on a “gross return” basis, that it will invest up to one per cent. per annum of its net asset value in drug development projects and that it will donate one per cent. per annum of its net asset value to charities including the Institute for Cancer Research (“ICR”) — will remain unchanged. Both the ICR and the managers of the underlying funds in which the Company currently invests are supportive of the proposed change. 

To date, neither the Investment Manager nor the BACIT investment management team have received a fee from the Company for their investment management services. Under the proposed arrangements, the personnel costs and operating expenses of the investment management function will be covered by a new fee payable by the Company to the Investment Manager equal to 0.19% per annum of the Company’s net asset value. It is not envisaged that the Investment Manager should make a meaningful profit from the fee. Notwithstanding the proposed changes to the expense arrangements Tom Henderson will continue to provide his services as a director of the Company and as CEO of the Investment Manager free of charge. 

A circular, including a notice of an extraordinary general meeting of the Company to approve the proposed changes to the expense arrangements intended to be held at 9.30 a.m. on 11 December 2015 at the offices of Northern Trust International Fund Administration Services (Guernsey) Limited, Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3QL will be sent to shareholders shortly. 

A copy of the circular, when published, be available on the Company's website at http://www.bacitltd.com. The Circular will also be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/nsm.

Enquiries:

Northern Trust International Fund Administration Services (Guernsey) Limited

Tel: +44 (0) 1481 745368

Date   Source Headline
11th Nov 20247:00 amRNSTransaction in Own Shares
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 202411:57 amRNSTotal Voting Rights
1st Nov 20247:00 amRNSTransaction in Own Shares
31st Oct 20247:00 amRNSTransaction in Own Shares
30th Oct 20247:00 amRNSTransaction in Own Shares
29th Oct 20247:00 amRNSTransaction in Own Shares
28th Oct 20247:00 amRNSTransaction in Own Shares
25th Oct 20247:00 amRNSTransaction in Own Shares
24th Oct 20247:00 amRNSTransaction in Own Shares
23rd Oct 20247:05 amRNSSpur presents positive data from Phase I/II trial
23rd Oct 20247:00 amRNSTransaction in Own Shares
22nd Oct 20247:00 amRNSTransaction in Own Shares
21st Oct 20247:00 amRNSTransaction in Own Shares
18th Oct 20247:00 amRNSNotice of Results
18th Oct 20247:00 amRNSTransaction in Own Shares
17th Oct 20247:00 amRNSTransaction in Own Shares
16th Oct 20247:00 amRNSTransaction in Own Shares
15th Oct 20243:05 pmRNSBeacon announces positive data from Phase II trial
15th Oct 20247:00 amRNSTransaction in Own Shares
14th Oct 20247:00 amRNSTransaction in Own Shares
11th Oct 20247:00 amRNSTransaction in Own Shares
10th Oct 20247:00 amRNSTransaction in Own Shares
9th Oct 20247:00 amRNSPurespring Therapeutics Series B financing
9th Oct 20247:00 amRNSTransaction in Own Shares
8th Oct 20247:00 amRNSTransaction in Own Shares
7th Oct 20247:00 amRNSTransaction in Own Shares
4th Oct 20247:00 amRNSTransaction in Own Shares
3rd Oct 20247:00 amRNSResolution Series B and new Chair appointment
3rd Oct 20247:00 amRNSTransaction in Own Shares
2nd Oct 20247:00 amRNSTransaction in Own Shares
1st Oct 20242:17 pmRNSTotal Voting Rights
1st Oct 20247:00 amRNSTransaction in Own Shares
30th Sep 20247:00 amRNSTransaction in Own Shares
26th Sep 20247:00 amRNSTransaction in Own Shares
25th Sep 20247:00 amRNSTransaction in Own Shares
24th Sep 20247:00 amRNSTransaction in Own Shares
23rd Sep 20247:00 amRNSTransaction in Own Shares
20th Sep 20247:00 amRNSDirectorate Change
20th Sep 20247:00 amRNSTransaction in Own Shares
19th Sep 20243:00 pmRNSBeacon presents clinical data update
19th Sep 202412:03 pmRNSAchilles announces strategic update
19th Sep 20247:00 amRNSTransaction in Own Shares
18th Sep 20247:00 amRNSTransaction in Own Shares
17th Sep 20247:00 amRNSTransaction in Own Shares
16th Sep 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.